Reader-exclusive · 10% off DoNotAge Ca-AKG on DoNotAge CODE BB10
DoNotAge Ca-AKG supplement bottle — 400 mg calcium alpha-ketoglutarate per capsule

DoNotAge · Ca-AKG · Physician-reviewed · #1 Ca-AKG pick

DoNotAge Ca-AKG Review — 400 mg Capsules, Human Evidence and Verdict

RECOMMENDED Product Review14 min readLast verified 21 Sep 2026
4.9/5Our #1 Ca-AKG pick for 2026: clean single-ingredient formulation, independent batch testing, stated 99.8% purity, practical 400 mg capsules, strong brand quality standards and good overall value.

What stands out

  • 400 mg of Ca-AKG per capsule in a simple plant-based capsule with no fillers, binders or unnecessary additives.
  • DoNotAge states that every batch is independently tested and that its ingredients are verified to a 99.8% purity standard.
  • Manufactured under GMP and ISO9001-certified systems, with climate-controlled storage and global fulfilment.
  • Practical dosing: 400 mg per capsule, 800 mg/day standard use, with a 1,600 mg/day annual subscription option for users who intentionally choose a higher intake.
  • Strong overall value for a specialist longevity product, with a $49 starting price and BB10 reader discount on eligible standalone purchases.

Things to know first

  • Standard-release DoNotAge Ca-AKG is not the proprietary delayed-release Rejuvant formulation used in the best-known DNA-methylation-age studies.
  • The exact retail DoNotAge capsule has not been tested as a finished product in a randomized longevity trial; its evidence chain comes from Ca-AKG research plus product-quality documentation.

Key takeaways

  • DoNotAge Ca-AKG is our #1 overall Ca-AKG recommendation for 2026 because it combines a clean single-ingredient formula, stated independent batch testing, practical dosing and strong value.
  • Each capsule contains 400 mg Ca-AKG; the standard recommendation is two capsules daily for 800 mg/day.
  • Human Ca-AKG evidence is strongest for oral metabolic exposure, bone-related outcomes and historical clinical use; the biological-age signal remains observational and formulation-specific.
  • DoNotAge states every batch is independently tested and its ingredients are verified to a 99.8% purity standard, with GMP and ISO9001 manufacturing.
  • The 60-capsule bottle lasts 30 days at 800 mg/day; annual subscriptions use 366-capsule containers and are dispatched as a single annual shipment.

Bottom line

Our #1 Ca-AKG pick for 2026. DoNotAge gives you a clean 400 mg standard-release capsule, an easy 800 mg/day routine, stated independent batch testing, a 99.8% purity standard and strong manufacturing credentials at a competitive starting price. The product earns the recommendation on quality and evidence fit—not by pretending the Rejuvant biological-age results or mouse lifespan findings are proven outcomes for this exact bottle.

Our verdict

DoNotAge Ca-AKG is our #1 overall Ca-AKG recommendation for 2026. It combines a clean single-ingredient standard-release formula, practical 400 mg capsules, an 800 mg/day default serving, stated independent batch testing, a 99.8% ingredient purity standard, GMP/ISO9001 manufacturing and competitive value. The product does not need to inherit Rejuvant-specific biological-age claims to earn that position: its strength is the quality of the finished-product proposition paired with a broad Ca-AKG evidence base.

Product facts and evidence re-checked September 21, 2026 against DoNotAge's current Ca-AKG information and the 63-paper Biohack Blueprint Ca-AKG evidence database. Biohack Blueprint did not independently laboratory-assay the current retail lot.
Reader-exclusive

DoNotAge Ca-AKG — via DoNotAge

Use code 10% off
  • 14-day money-back guarantee
  • 30-day supply per bottle
  • Subscribe & save available
  • Fast shipping from DoNotAge
Get 10% off on DoNotAge with BB10 →

DoNotAge handles pricing, fulfilment, and customer support for this product. Biohack Blueprint may earn a commission from purchases made through links on this page, at no extra cost to you. This does not affect our evidence grading or editorial verdict.

Physician-authored #1 Ca-AKG pick 63-paper evidence base Independent batch testing stated 99.8% purity standard stated GMP & ISO9001 BB10 saves 10%

Who this is for

Good fit if you're...

Longevity-focused adults

Best suited to adults who want a simple daily Ca-AKG product from a specialist longevity brand.

Clean-label buyers

A strong fit if you prefer a single active ingredient, plant-based capsule and no unnecessary fillers.

Existing DoNotAge users

Easy to add to a DoNotAge-focused stack, with BB10 available on eligible standalone purchases.

Evidence-conscious supplement users

A good fit if you value human Ca-AKG pharmacology and bone evidence but accept that longevity outcomes remain under study.

Probably not for you if...

Buyers who require the exact Rejuvant study formulation

Choose the studied controlled-release Rejuvant formulation if exact formulation matching to those observational biological-age papers is your overriding priority.

People with complex calcium-sensitive medication timing

Discuss with a clinician or pharmacist first if your medicines are known to interact with oral calcium.

Key facts & composition

Per capsule 400 mg Ca-AKG Calcium alpha-ketoglutarate salt mass
Recommended daily serving 800 mg/day 2 capsules daily
Retail bottle 60 capsules 30 days at the standard serving
Current starting price From $49 Price checked September 21, 2026
Quality testing Independent batch testing stated DoNotAge also states a 99.8% ingredient purity standard
Money-back guarantee 14 days Full refund unopened; partial refund terms apply to opened products

Composition

Ingredient Amount Form Source
Calcium alpha-ketoglutarate (Ca-AKG) 800 mg/day (2 × 400 mg capsules) Standard-release calcium alpha-ketoglutarate DoNotAge single-ingredient capsule

DoNotAge lists 400 mg of Ca-AKG per plant-based capsule with no fillers or unnecessary additives. The label amount is Ca-AKG salt mass; the current product page does not separately state elemental calcium or AKG base mass.

How it works

Ca-AKG is not a stimulant and does not work through one single anti-aging pathway. Alpha-ketoglutarate sits inside central metabolism while also acting as a co-substrate for epigenetic enzymes and interacting with nutrient, immune and senescence signaling. The review separates these mechanisms from human outcomes so plausible biology is not mistaken for proven longevity efficacy.

1

TCA-cycle metabolism and cellular energy

Alpha-ketoglutarate is an endogenous intermediate in the tricarboxylic acid cycle and a metabolic junction between carbon and nitrogen metabolism. Oral AKG has measurable human metabolic exposure, so this is not merely a cell-culture mechanism; what remains uncertain is how much chronic supplementation changes clinically meaningful energy or aging outcomes in healthy adults.

2

AKG-dependent enzymes and epigenetic regulation

AKG is a required co-substrate for dioxygenases including TET DNA-demethylation enzymes and JmjC histone demethylases. This creates a biologically plausible link between AKG availability and epigenetic state, but human DNA-methylation-age findings come from observational delayed-release Rejuvant cohorts rather than a completed randomized trial of standard DoNotAge Ca-AKG.

3

Nutrient, immune and senescence signaling

Experimental studies connect AKG with mTOR/AMPK signaling, macrophage metabolism, senescence-associated secretory signaling and mitochondrial function. These pathways help explain why Ca-AKG is interesting as a geroscience ingredient, but the direction and magnitude of effects are context-dependent and should not be translated directly into a claim of proven human lifespan extension.

This review draws on 23 peer-reviewed papers indexed in our Calcium alpha-ketoglutarate Data Center →

The evidence

The grades below describe the strength of the Ca-AKG/AKG evidence for each claim, not whether DoNotAge makes a high-quality capsule. Human pharmacology and the osteopenia trial are substantially stronger than the lifespan, senescence, muscle or biological-age claims that dominate longevity marketing.

B

Oral AKG reaches human metabolic circulation and changes measurable metabolic markers

Tier 2

Controlled human studies demonstrate that orally administered AKG-containing preparations produce measurable systemic exposure and metabolic effects. This supports the basic plausibility of standard oral Ca-AKG rather than requiring a special delivery technology for biological activity.

Mittal G et al. 2010, Cynober L et al. 1990

B

Ca-AKG can affect bone-turnover biology in postmenopausal osteopenia

Tier 2

A six-month randomized double-blind trial in postmenopausal women with osteopenia found a significant reduction in the bone-resorption marker CTX with Ca-AKG plus calcium versus calcium alone. This is the cleanest modern human efficacy signal for Ca-AKG, although it is a biomarker outcome rather than proof of fracture prevention.

Filip RS et al. 2007

C

Ca-AKG may be associated with lower DNA-methylation biological age

Tier 2

Rejuvant studies reported favorable DNA-methylation-age associations, including a 2026 cohort in which delayed-release AKG users had a lower cross-sectional Age Residual. The adjusted longitudinal association was not significant, and the formulation contained additional vitamins. ABLE is the key randomized aging trial, but efficacy results are not yet available.

Oleksandr Demidenko et al. 2021, Kamil Pabis et al. 2026, Elena Sandalova et al. 2023, Lim ZM et al. 2025

D

Ca-AKG extends lifespan

Tier 3

The 2020 C57BL/6 mouse study reported healthspan benefits and female lifespan extension, but two later NIA Interventions Testing Program experiments in genetically heterogeneous UM-HET3 mice did not reproduce a lifespan increase. No human lifespan study exists.

Azar Asadi Shahmirzadi et al. 2020, Miller RA et al. 2024, Korstanje R et al. 2026

D

Ca-AKG reduces age-related inflammatory or senescence signaling

Tier 3

Mouse and cell studies support effects on SASP-associated signaling, macrophage metabolism and inflammatory pathways. These findings are biologically relevant but have not yet become a completed randomized human anti-inflammatory efficacy program for Ca-AKG.

Azar Asadi Shahmirzadi et al. 2020, Liu PS et al. 2017, Akakura S et al. 2025

D

Ca-AKG improves muscle function, frailty or sarcopenia in aging humans

Tier 3

AKG has substantial muscle-regeneration and sarcopenia biology in animal and mechanistic models, and related alpha-keto-acid interventions have human exercise data. A completed Ca-AKG randomized trial demonstrating improved sarcopenia or frailty in older adults is still lacking.

Zhang Y et al. 2025, Ciuffoli V et al. 2024, Miaomiao Xu et al. 2024

How it compares

DoNotAge Ca-AKGRenue By Science CaAKG Rejuvant LifeAKG
Standard daily serving 800 mg/day Renue: label-dependent CaAKG serving Rejuvant: ~1,000 mg/day controlled release
Release / delivery Standard capsule Renue: liposomal capsule Rejuvant: controlled release
Formula simplicity Single-ingredient Ca-AKG; no fillers/additives stated Single CaAKG product with liposomal delivery system Ca-AKG plus sex-specific vitamins
Testing transparency Independent testing + stated 99.8% purity standard Strong public batch-number testing archive Third-party testing stated
Match to biological-age studies Standard Ca-AKG; not the Rejuvant formulation Different liposomal formulation Closest formulation match
Current starting price From $49 About $48.95 About $99.95 / 30 days
Biohack Blueprint position #1 overall Ca-AKG pick Best for granular public batch documentation Best for exact Rejuvant-study formulation match

Clinical pharmacology

DoNotAge recommends 800 mg/day. The ABLE aging trial uses 1,000 mg/day sustained-release Ca-AKG for six months, while older human Ca-AKG studies used gram-level exposures for metabolic, renal or bone questions. There is no validated longevity dose-response curve showing that 1,000 or 1,600 mg/day is automatically superior to 800 mg/day.

Dose tiers

TierDoseFrequencyDurationNotes
DoNotAge standard serving 800 mg/day Daily Ongoing label use

Two 400 mg capsules daily. This is the current DoNotAge recommended serving and the dose used in our product-value calculations.
Modern aging-trial anchor 1,000 mg/day Daily 6 months

ABLE uses 1 g/day sustained-release Ca-AKG for six months. This is a useful research anchor, but it is a different controlled-release formulation from DoNotAge's standard capsule.
DoNotAge higher subscription option 1,600 mg/day Daily Annual subscription supply

DoNotAge currently offers a 1,600 mg/day subscription option. Human dose-ranging trials have not established that this higher intake produces greater longevity benefit than 800 or 1,000 mg/day.

From bench to bedside

PathwayPreclinical findingHuman translationConfidence
TET / epigenetic dioxygenases AKG availability can influence TET-dependent DNA demethylation and senescence-state plasticity. Human biological-age associations exist, but they are observational and formulation-specific rather than randomized proof of epigenetic rejuvenation. Moderate mechanism / low-to-moderate clinical translation
mTOR / AMPK nutrient signaling AKG can alter ATP synthase, TOR/mTOR and AMPK-related signaling in several experimental models. No human trial has shown that oral Ca-AKG improves longevity by clinically suppressing mTOR or activating AMPK. Moderate preclinical / low clinical
Senescence-associated secretory phenotype (SASP) Ca-AKG reduced selected SASP/inflammatory signals in the foundational mouse-aging program without establishing senescent-cell clearance. Useful as a mechanistic rationale, but no randomized human Ca-AKG trial has yet demonstrated a senomorphic clinical outcome. Moderate preclinical / low clinical

Drug interactions

Potential timing interaction

Levothyroxine and other calcium-sensitive oral medicines

The product is a calcium salt; oral calcium can reduce absorption of some medicines, although DoNotAge does not state the product's elemental calcium amount.

Recommendation:

If you take levothyroxine, ask your pharmacist or clinician how to space Ca-AKG from the medicine. NIH guidance for calcium carbonate advises a four-hour separation; the exact interaction magnitude for Ca-AKG itself has not been specifically studied.

Potential absorption interaction

Quinolone antibiotics

Calcium can chelate some quinolone antibiotics and reduce their absorption.

Recommendation:

Use clinician/pharmacist guidance for spacing if taking ciprofloxacin, moxifloxacin or related quinolones. NIH guidance for calcium supplements commonly uses at least a two-hour separation; product-specific Ca-AKG interaction studies are lacking.

Potential clinically important interaction

Dolutegravir / HIV integrase inhibitors

Calcium-containing supplements can reduce dolutegravir exposure through chelation under fasting conditions.

Recommendation:

Do not improvise timing if you use dolutegravir or a related regimen. FDA/NIH guidance allows calcium with dolutegravir when taken with food, or otherwise recommends dolutegravir two hours before or six hours after calcium supplements.

Bioavailability tips

Standard oral AKG and Ca-AKG have demonstrated human metabolic exposure, so a liposomal or delayed-release system is not required to show that oral AKG can be biologically active. No head-to-head human trial has established a clinically superior delivery system for longevity. Take the product consistently and use medication-spacing guidance if a calcium-sensitive drug is part of your regimen.

Special populations

PopulationRecommendationRationale
Pregnancy or breastfeeding Avoid routine use unless specifically approved by your clinician

There is not enough pregnancy- or lactation-specific Ca-AKG safety evidence to support routine longevity supplementation in these groups.
Kidney disease, dialysis or abnormal calcium/phosphate balance Use only with clinician supervision

Ca-AKG has historical clinical use in dialysis populations, but kidney disease changes mineral handling and medication complexity. Modern longevity dosing should not be self-directed in this setting.
Children and adolescents Not intended for routine longevity use

The product is formulated for adults, and there is no established pediatric longevity indication or dosing framework.
Active cancer treatment Discuss with the oncology team before use

AKG participates in epigenetic and tumor-metabolism pathways. Preclinical studies are interesting but context-dependent, and they do not justify using Ca-AKG as a cancer treatment or adding it during therapy without oncology review.

Therapeutic positioning

DoNotAge earns our #1 Ca-AKG position on the overall package rather than a single headline metric. Renue is excellent for granular public batch documentation, Rejuvant most closely matches the proprietary controlled-release biological-age formulation, and Toniiq competes aggressively on labeled dose and price. DoNotAge gives us the best balance of formulation simplicity, testing standards, dosing usability, specialist longevity positioning and reader value.

Renue By Science CaAKG

Direct Ca-AKG competitor DoNotAge #1 overall; Renue strongest for public batch-document granularity

Renue offers unusually granular public batch documentation and a liposomal formulation. No randomized human trial has shown that liposomal Ca-AKG is clinically superior to standard Ca-AKG. DoNotAge remains our overall pick for its balance of clean formulation, testing standards, brand focus, practical dosing and reader value.

Rejuvant LifeAKG

Controlled-release Ca-AKG comparator DoNotAge #1 overall; Rejuvant best formulation-match to biological-age studies

Rejuvant is the closest match to the delayed-release formulation used in the biological-age observational literature and the ABLE protocol. It is also a more complex, higher-priced formulation with added vitamins. DoNotAge is the cleaner single-ingredient choice and our #1 overall retail recommendation.

Toniiq Calcium AKG 1500

High-dose value competitor DoNotAge #1 overall; Toniiq strongest for high labeled dose at low current price

Toniiq emphasizes a higher labeled serving and low bottle price. Human Ca-AKG evidence does not establish a simple dose-response in which more milligrams automatically produce more benefit. We prefer DoNotAge's overall quality/testing/brand package rather than ranking by milligrams alone.

Ca-AKG is an optional longevity intervention, not a substitute for exercise, adequate protein and micronutrients, sleep, blood-pressure control, metabolic health or evidence-based treatment. Those fundamentals have much stronger evidence for healthspan than any current Ca-AKG supplement.

This product is not a treatment for osteoporosis, cancer, diabetes, sarcopenia, fatigue or other disease, and no Ca-AKG supplement has demonstrated human lifespan extension. Use it as a supplement to—not a replacement for—appropriate medical care.

About buying through us

Is 800 mg too low compared with the 1,000 mg used in modern Ca-AKG studies?

Not necessarily. One gram per day is a useful modern research anchor, but there is no validated dose-response trial proving that 1,000 mg is superior to 800 mg for longevity. The ABLE dose is also sustained release, so formulation differs as well as dose.

Why choose DoNotAge instead of Rejuvant?

Rejuvant is the better match if your only goal is to reproduce the exact controlled-release formulation used in its biological-age observational studies. We rank DoNotAge #1 overall because it is a simpler single-ingredient product with strong testing standards, practical dosing, substantially lower starting cost and no added vitamin confounders.

Would liposomal Ca-AKG be better absorbed?

A liposomal formulation may be marketed for delivery advantages, but no randomized human Ca-AKG trial has shown superior clinical bioavailability or aging outcomes versus standard Ca-AKG. Oral AKG and Ca-AKG already have human metabolic exposure data.

Should I use the 1,600 mg/day subscription option?

DoNotAge offers it, but higher is not automatically better. There is no longevity dose-ranging trial showing that 1,600 mg/day produces more benefit than 800 or 1,000 mg/day. Choose higher intake only with a clear rationale, especially if you have medication or mineral-balance considerations.

Has the exact DoNotAge Ca-AKG product been clinically tested?

The exact retail capsule has not been tested as a finished product in a randomized longevity trial. The evidence chain comes from human Ca-AKG/AKG studies, preclinical aging research and DoNotAge's product-quality documentation.

Reader questions

Is DoNotAge Ca-AKG a good supplement?

Yes. It is our #1 overall Ca-AKG recommendation for 2026 because the product combines a clean single-ingredient formula, practical 400 mg capsules, stated independent batch testing, a 99.8% ingredient purity standard, GMP/ISO9001 manufacturing and competitive value. The recommendation is based on product quality and evidence fit, not on a claim that Ca-AKG has proven human lifespan extension.

How much Ca-AKG is in DoNotAge?

Each capsule contains 400 mg of calcium alpha-ketoglutarate. DoNotAge's standard serving is two capsules daily, providing 800 mg/day. The annual subscription also offers a 1,600 mg/day option.

Is DoNotAge Ca-AKG third-party tested?

DoNotAge states that every batch is independently tested for identity, purity and composition and that its ingredients are verified to a 99.8% purity standard. The product is also described as being manufactured under GMP and ISO9001-certified systems.

Does DoNotAge Ca-AKG reverse biological age?

That has not been demonstrated. The best-known biological-age results come from observational studies of Rejuvant, a different delayed-release Ca-AKG-plus-vitamins formulation. DoNotAge uses standard-release single-ingredient Ca-AKG. The randomized ABLE trial is designed to test biological-age outcomes with sustained-release Ca-AKG, but efficacy results are not yet published.

Is DoNotAge Ca-AKG delayed release?

No. It is a standard-release Ca-AKG capsule. No randomized head-to-head trial has shown that delayed-release or liposomal Ca-AKG produces better clinical outcomes than standard-release Ca-AKG.

When should I take DoNotAge Ca-AKG?

There is no validated best time of day. Consistent daily use matters more than a precise clock time. If you take medicines that can interact with oral calcium, discuss timing with a pharmacist or clinician.

Can I take DoNotAge Ca-AKG with medication?

Possibly, but the calcium component means timing can matter with medicines such as levothyroxine, quinolone antibiotics and dolutegravir. The exact elemental calcium content of the current Ca-AKG page is not stated, so use clinician or pharmacist guidance rather than assuming the interaction is negligible.

Does BB10 work on DoNotAge Ca-AKG?

Yes. BB10 is Biohack Blueprint's reader code for eligible standalone DoNotAge products and gives 10% off. Biohack Blueprint may earn a commission when readers purchase through our affiliate link.

Editorial credibility

Portrait of Dr. Khaled Mahmoud, ICU physician and founder of Biohack Blueprint

Author

Dr. Khaled Mahmoud, MBBCh

MBBCh

Critical Care Medicine, Longevity Science & Editorial Direction

Portrait of Dr. Amr Yasser, cardiometabolic and musculoskeletal reviewer for Biohack Blueprint

Reviewer

Dr. Amr Yasser, PhD

MBBCh, PhD, General Surgery, Cardiometabolic Medicine, Musculoskeletal Research

Cardiometabolic, Musculoskeletal, Gut & Bioavailability

Portrait of Dr. Abdulla Mostafa, neuroscience reviewer for Biohack Blueprint

Reviewer

Dr. Abdulla Mostafa, PhD

MBBCh, PhD, Neuroscience, Neurosurgery

Cellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology

Our #1 Ca-AKG pick for 2026: clean single-ingredient formulation, independent batch testing, stated 99.8% purity, practical 400 mg capsules, strong brand quality standards and good overall value.

Related reading

Calcium alpha-ketoglutarate: benefits, dose and evidence

Shahmirzadi 2020 Ca-AKG study: what it found and what replication changed

What is Ca-AKG supplement? A plain-English guide

How does Ca-AKG work? Mechanisms explained

Ca-AKG vs AAKG: which one, and why they're different

Ca-AKG vs AKG: does the calcium binding really matter?

AKG forms explained: Ca-AKG, AAKG, OAKG, and the rest

Ca-AKG dosage: what the trial data actually supports

When to take Ca-AKG: what actually matters (and what doesn't)

Ca-AKG and autophagy: what the evidence actually shows

Ca-AKG stacking: pairing with NMN, fisetin and other longevity supplements

Ca-AKG and biological age: the Rejuvant story, the ABLE trial, and what we actually know

Ca-AKG for bone health: the postmenopausal osteopenia evidence

Ca-AKG and grey hair: what the mouse study actually showed

Ca-AKG for muscle, frailty and sarcopenia

Ca-AKG and inflammation: the SASP, cytokines and inflammaging picture

Ca-AKG for weight loss and fatty liver: what the metabolic data supports

Ca-AKG side effects and safety profile

Ca-AKG dietary sources: foods that contain alpha-ketoglutarate

Ca-AKG and cancer: the honest evidence check

Ca-AKG and fisetin: pairing a Krebs cycle metabolite with a senolytic

Ca-AKG vs NMN: mechanisms and human evidence compared

Ca-AKG vs Urolithin A: human evidence and mechanisms compared

Best Ca-AKG supplement: a clinician's buying guide
  1. Alpha-Ketoglutarate dietary supplementation to improve health in humans Gyanwali B, Lim ZX, Soh J, Lim C, Guan SP, Maier AB, Goh J, Kennedy BK (2022) . Trends in Endocrinology and Metabolism Read on our Data CenterView on PubMed DOI
  2. Radiolabeling and dose fixation study of oral alpha-ketoglutarate as a cyanide antidote in healthy human volunteers Mittal G, Singh T, Kumar N, Bhatnagar A, Tripathi RP, Tulsawani R, Vijayaraghavan R, Bhattacharya R (2010) . Clinical Toxicology Read on our Data CenterView on PubMed DOI
  3. Action of ornithine alpha-ketoglutarate, ornithine hydrochloride, and calcium alpha-ketoglutarate on plasma amino acid and hormonal patterns in healthy subjects Cynober L, Coudray-Lucas C, de Bandt JP, Guéchot J, Aussel C, Salvucci M, Giboudeau J (1990) . Journal of the American College of Nutrition Read on our Data CenterView on PubMed DOI
  4. Alpha-Ketoglutarate Decreases Serum Levels of C-terminal Cross-Linking Telopeptide of Type I Collagen (CTX) in Postmenopausal Women with Osteopenia: Six-Month Study Filip RS, Pierzynowski SG, Lindegard B, Wernerman J, Haratym-Maj A, Podgurniak M (2007) . International Journal for Vitamin and Nutrition Research Read on our Data CenterView on PubMed DOI
  5. Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test Oleksandr Demidenko, Diogo Barardo, Valery Budovskii, Robb Finnemore, Francis R. Palmer III, Brian K. Kennedy, Yelena V. Budovskaya (2021) . Aging (Albany NY) Read on our Data CenterView on PubMed View on PMC DOI
  6. Supplements and Drugs Are Associated With Biological Age in a Cohort of Exceptionally Healthy Individuals Kamil Pabis, Weilan Wang, Kumar Selvarajoo, Yelena V. Budovskaya, Vincenzo Sorrentino, Jan Gruber, Brian K. Kennedy (2026) . Aging Cell Read on our Data CenterView on PubMed View on PMC DOI
  7. Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol Elena Sandalova, Jorming Goh, Zi Xiang Lim, Zhi Meng Lim, Diogo Barardo, Rajkumar Dorajoo, Brian K. Kennedy, Andrea B. Maier (2023) . GeroScience Read on our Data CenterView on PubMed View on PMC DOI Clinical Trial
  8. Recruitment evaluation of a gerotherapeutic randomized controlled trial testing alpha-ketoglutarate in biologically older, middle-aged adults (ABLE) Lim ZM, Chew YE, Guan L, Wang W, Mahadzir MDA, Dorajoo R, Kennedy BK, Sandalova E, Maier AB (2025) . Experimental Gerontology Read on our Data CenterView on PubMed DOI Clinical Trial
  9. Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice Azar Asadi Shahmirzadi, Daniel Edgar, Chen-Yu Liao, Yueh-Mei Hsu, Mark Lucanic, Arash Asadi Shahmirzadi, Christopher D. Wiley, Garbo Gan, Dong Eun Kim, Herbert G. Kasler, Chisaka Kuehnemann, Brian Kaplowitz, Dipa Bhaumik, Rebeccah R. Riley, Brian K. Kennedy, Gordon J. Lithgow (2020) . Cell Metabolism Read on our Data CenterView on PubMed View on PMC DOI
  10. Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestradiol, and late-start canagliflozin Miller RA, Harrison DE, Cortopassi GA, Dehghan I, Fernandez E, Garratt M, Geisler JG, Ginsburg BC, Han ML, Jiang N, Kaczorowski CC, Kumar N, Leiser SF, Lopez-Cruzan M, Milne G, Mitchell JR, Nelson JF, Reifsnyder PC, Salmon AB, Xu Z, Korstanje R, Rosenthal N, Strong R (2024) . GeroScience Read on our Data CenterView on PubMed View on PMC DOI
  11. Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice Korstanje R, Strong R, Salmon AB, Bogue MA, Curran SP, Diaz V, Fernandez E, Ginsburg B, Han M, Harrison DE, Kaczorowski C, Kaeberlein M, Kennedy BK, Kumar N, LaCroix-Fralish M, Leiser SF, Nelson JF, Polymenis M, Reifsnyder PC, Rosenthal NA, Silva E, Tower J, Miller RA (2026) . GeroScience Read on our Data CenterView on PubMed View on PMC DOI
  12. Calcium alpha-ketoglutarate administration to malnourished hemodialysis patients improves plasma arginine concentrations Riedel E, Hampl H, Steudle V, Nündel M (1996) . Mineral and Electrolyte Metabolism Read on our Data CenterView on PubMed
  13. Long-term treatment with calcium-alpha-ketoglutarate corrects secondary hyperparathyroidism Zimmermann E, Wassmer S, Steudle V (1996) . Mineral and Electrolyte Metabolism Read on our Data CenterView on PubMed
  14. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B (1998) . American Journal of Kidney Diseases Read on our Data CenterView on PubMed DOI
  15. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ (1999) . Nephrology Dialysis Transplantation Read on our Data CenterView on PubMed DOI
  16. Toxicity of alpha-ketoglutarate following 14-days repeated oral administration in Wistar rats Bhattacharya R, Gujar N, Singh P, Rao P, Vijayaraghavan R (2011) . Cellular and Molecular Biology Read on our Data CenterView on PubMed DOI
  17. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, Di Conza G, Cheng WC, Chou CH, Vavakova M, Muret C, Debackere K, Mazzone M, Huang HD, Fendt SM, Ivanisevic J, Ho PC (2017) . Nature Immunology Read on our Data CenterView on PubMed DOI
  18. AKG-TET axis is central to senescence plasticity Akakura S, Tabibzadeh S (2025) . iScience Read on our Data CenterView on PubMed View on PMC DOI
  19. α-Ketoglutarate Ameliorates Sarcopenia in D-Galactose-Induced Aging Mice by Modulating Protein Homeostasis and Optimizing Mitochondrial Function Zhang Y, Wang H, Zhang Y, Wang X, Qiao Z, Wang J, Li Y, Sun Y (2025) . Nutrients Read on our Data CenterView on PubMed View on PMC DOI
  20. Psat1-generated α-ketoglutarate and glutamine promote muscle stem cell activation and regeneration Ciuffoli V, Feng X, Jiang K, Acevedo-Luna N, Ko KD, Wang AHJ, Riparini G, Khateb M, Glancy B, Dell'Orso S, Sartorelli V (2024) . Genes & Development Read on our Data CenterView on PubMed View on PMC DOI
  21. Impact of Alpha-Ketoglutarate on Skeletal Muscle Health and Exercise Performance: A Narrative Review Miaomiao Xu, Qiao Zhang, Xiaoguang Liu, Liming Lu, Zhaowei Li (2024) . Nutrients Read on our Data CenterView on PubMed View on PMC DOI
  22. Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK Su Y, Wang T, Wu N, Li D, Fan X, Xu Z, Mishra SK, Yang M (2019) . Aging (Albany NY) Read on our Data CenterView on PubMed View on PMC DOI
  23. The metabolite alpha-ketoglutarate extends lifespan by inhibiting the ATP synthase and TOR Chin RM, Fu X, Pai MY, Vergnes L, Hwang H, Deng G, Diep S, Lomenick B, Meli VS, Monsalve GC, Hu E, Whelan SA, Wang JX, Jung G, Solis GM, Fazlollahi F, Kaweeteerawat C, Quach A, Nili M, Krall AS, Godwin HA, Chang HR, Faull KF, Guo F, Jiang M, Trauger SA, Saghatelian A, Braas D, Christofk HR, Clarke CF, Teitell MA, Petrascheck M, Reue K, Jung ME, Frand AR, Huang J (2014) . Nature Read on our Data CenterView on PubMed View on PMC DOI

Ready to try DoNotAge Ca-AKG?

Use code BB10 for 10% off on DoNotAge.

Shop DoNotAge Ca-AKG on DoNotAge →

14-day money-back guarantee

First published 21 Sep 2026 · Last verified 21 Sep 2026